LFST · LifeStance Health Group
Conviction · Low · more likely to lag the S&P 500 over the next three months
Wrong if: a daily close above $15.95
Note written ·
How this view changed
- · Rated Low. Company news, 9 November 2026: Existing stockholders priced a 45-million-share secondary offering at $13.12 per share, below the $14.60 close, with the company repurchasing 2 million shares.
Price against the kill line
11.7% clear of its kill line on the 13 November 2026 close.
How to read this
This note expects the shares to lag the market, so its kill line sits above the price: a close above the red mark would prove the view wrong. Prices run from low on the left to high on the right. The dot is where the stock closed on 13 November 2026, left of the mark while it is below the line; a dot right of the mark has closed through it.
The scale is stretched near the line, so close calls are easy to see. More than 8% from the line, the stock reads well clear, with a hollow dot to show the figure is off the drawn scale.
The kill line is the research note's own test. The portfolio sells on business facts, not on a price. How the portfolio decides
Three months against the kill line
Daily closes, to . Red: the kill line, a daily close above $15.95, on record since 11 November 2026. The shares are up 12.2% since the close; the S&P 500 is down 2.1% over the same sessions. Figures in the note can cover a different window.
Kill line
A daily close above $15.95, beyond the $15.66 intraday 52-week high of 5 November 2026, which would show the shares leading the S&P 500; fourth-quarter adjusted EBITDA above the $64 million top of guidance would also count against this call.
Research onlyNot in the portfolio.
Key figures from the filings · Health Care
Quarter to 30 September 2026, filed 5 November 2026; valuation at the 13 November 2026 close
- Revenue, latest quarter ($M)
- 456
- Revenue, change on a year (%)
- +25.3
- Operating margin (%)
- 7.3
- Free cash flow, four quarters ($M)
- 179
- Net cash, cash less debt ($M)
- −53.1
- Price to earnings (×)
- 74.4
- Enterprise value to sales (×)
- 3.2
- Enterprise value to operating income (×)
- 51.9
All filed numbers
What LifeStance Health Group reports to the SEC in its quarterly and annual filings. Each group states its period and filing date once; a figure dated otherwise says so. Built from the filings known on .
| Quarter to | Revenue ($M) | On a year (%) | Operating margin (%) |
|---|---|---|---|
| first filed | 456 | +25.3 | 7.3 |
| first filed | 435 | +26.1 | 7.0 |
| first filed | 404 | +21.2 | 5.5 |
| first filed | 382 | +17.4 | 4.7 |
| first filed | 364 | +16.3 | 2.0 |
| first filed | 345 | +10.6 | −0.9 |
| Pre-tax income ($M) | 27.4 |
| Net income ($M) four quarters: 71.9 | 22.4 |
| Diluted shares, change on a year (%) against the quarter to 30 September 2025 | +0.6 |
| Operating cash flow ($M) | 228 |
| Capital spending ($M) | 48.3 |
| Free cash flow ($M) | 179 |
| Cash and short-term investments ($M) | 219 |
| Debt ($M) long-term debt | 272 |
| Net cash, cash less debt ($M) | −53.1 |
| Deferred revenue ($M) | Not reported |
| Backlog, orders not yet delivered ($M) | Not reported |
| Receivables ($M) | 121 |
| Inventory ($M) | Not reported |
| Shareholders' equity ($M) | 1,492 |
| Market value ($M) | 5,353 |
| Enterprise value, market value plus net debt ($M) | 5,406 |
| Enterprise value to sales (×) | 3.2 |
| Enterprise value to operating income (×) | 51.9 |
| Price to earnings (×) | 74.4 |
| Price to book value (×) | 3.6 |
| Free-cash-flow yield (%) | 3.3 |
Short interest (FINRA, settled 15 October 2026, published 26 October 2026): 3.6% of shares outstanding sold short, 4.8 days of average trading to cover, −11.2% since the previous report.
| Window | Bought | Sold |
|---|---|---|
| 90 daysfrom | $0 | $270.0M |
| 12 monthsfrom | $0 | $890.4M |
The thesis
LifeStance Health shares are more likely to lag the S&P 500 over the next three months. The business is improving, but existing stockholders keep selling stock into that improvement. The fourth-quarter report, estimated for late February 2027, settles whether margin growth can outrun the supply.
The rating is Low because of a dated supply event and a weak price reaction to strong results. Existing stockholders priced a 45-million-share secondary offering at $13.12 on 9 November 2026, below that day's $14.60 close, per the company's announcement reported by Investing.com. It was the fourth underwritten holder sale of 2026, and LifeStance receives no proceeds.
The results themselves were strong. Third-quarter adjusted earnings before interest, taxes, depreciation and amortization (adjusted EBITDA) was $68.4 million, above the company's $49–59 million guidance, per its 5 November 2026 8-K exhibit. Full-year adjusted-EBITDA guidance rose to $242–250 million from $215–235 million. Barclays raised its target to $18 from $15 on 11 November 2026 and kept an Overweight rating. The price already reflects much of this: the shares are up 17.6% over three months in adjusted daily closes to $14.37 on 11 November 2026, more than double the $6.18 closing low of 19 November 2025.
Bullish and bearish views on LifeStance Health Group, Inc.
The bull case on LifeStance Health Group, Inc. (LFST), in brief: third-quarter profit cleared guidance. The bear case: holders sold the largest block of 2026.
Bull case
- Third-quarter profit cleared guidance. Adjusted EBITDA rose 70% to $68.4 million, or 15.0% of revenue, the company reported on 5 November 2026. Net income was $22.4 million, against $1.1 million a year earlier.
- Revenue and outlook beat estimates. Third-quarter revenue rose 25% to $455.9 million, against a $431.8 million estimate cited by Benzinga on 5 November 2026. Full-year revenue guidance rose to $1.741–1.761 billion, against a $1.709 billion estimate.
- Visits outgrew clinicians. Visits rose 17% to 2.7 million while clinicians rose 11% to 8,863, per the 5 November 2026 release. More visits per clinician lifts profit without matching growth in staff.
- Management expects wider margins. Chief Financial Officer Ryan McGroarty said on the 5 November 2026 call that margins should keep expanding in 2027 and beyond. He said 20% is not a ceiling for the 15%–20% long-term adjusted-EBITDA margin range.
- Four brokers raised targets after the report. BTIG raised its target to $20 (Buy) on 5 November 2026. Canaccord Genuity moved to $16 (Buy) and KeyBanc to $17 (Overweight) on 6 November 2026, per Benzinga, and Barclays to $18 (Overweight) on 11 November 2026.
- The company keeps buying back stock. LifeStance agreed on 9 November 2026 to repurchase 2 million shares from the offering underwriters at $13.12. It repurchased $25 million of stock in the third quarter, per the 5 November 2026 release.
Bear case
- Holders sold the largest block of 2026. The 45 million shares priced at $13.12 on 9 November 2026, underwritten by Barclays and J.P. Morgan, exceed any earlier 2026 offering. The company's 2-million-share repurchase absorbs only a small part.
- Selling has come in waves. Holders sold 25 million shares at $7.04 in February 2026, with TPG selling about 20.7 million, per Reuters. Holders sold 22.25 million shares at $12.35 in September, and TPG reported selling 18,409,705 shares at $12.29 on 11 September 2026 in an SEC Form 4.
- Insiders are sellers too. Director Kenneth Burdick sold 500,000 shares at $11.51 on 11 August 2026, per his Form 4. Executive Ryan Pardo filed a Form 144 notice of a proposed stock sale on 10 November 2026.
- The shares faded on report day. On 5 November 2026 the shares reached the $15.66 intraday 52-week high, then closed at $13.43, below the $14.21 close of 4 November 2026.
- Fourth-quarter profit guidance steps down. The $56–64 million fourth-quarter adjusted-EBITDA guidance sits below the $68.4 million third-quarter result, per the 5 November 2026 release.
- Rate growth is set to slow. Total revenue per visit rose 7% to $170 in the third quarter, mainly on payer rate increases. The CFO called low to mid-single digits the right 2027 rate planning range on the 5 November 2026 call.
Price setup
The shares closed at $14.37 on 11 November 2026, down from $14.60 on 9 November 2026 and $14.56 on 10 November 2026. The 52-week intraday high is $15.66, set on 5 November 2026; the last close is 8.2% below it. The three-month gain is 17.6%, measured from a $12.22 close on 13 August 2026.
The 50-day moving average stands at $12.74 and the 200-day at $9.60, both as of 11 November 2026, so the shares trade well above both. Two offering prices sit beneath the last close: $13.12 from the 9 November 2026 sale and $12.35 from the September sale. A close back under $13.12 would put the shares below the price at which the latest buyers took 45 million shares.
The case turns on whether the shares can clear the 5 November 2026 intraday high while holders still own stock to sell. The fourth-quarter report is the next scheduled company event; the fourth-quarter 2025 report came on 25 February 2026.
Catalysts ahead
- ~25 February 2027 (est.): Fourth-quarter and full-year 2026 report, with 2027 guidance. Tests the $56-64M fourth-quarter adjusted-EBITDA guidance and management's statement that margins keep expanding in 2027 as payer rate growth slows to low to mid-single digits.
What would change the view
A daily close above $15.95, beyond the $15.66 intraday 52-week high of 5 November 2026, which would show the shares leading the S&P 500; fourth-quarter adjusted EBITDA above the $64 million top of guidance would also count against this call.
What it trades with
LifeStance trades as an outpatient mental-health provider whose revenue depends on commercial insurers. UnitedHealthcare and Elevance Health accounted for 14% and 15% of fiscal 2025 revenue, so their reimbursement news bears directly on revenue per visit. Secondary offerings by holders such as TPG and Summit Partners have moved the shares on their own schedule, separate from quarterly results.
The evidence, claim by claim (8)
- Existing stockholders priced a secondary offering of 45,000,000 shares at $13.12; LifeStance receives no proceeds and will repurchase 2,000,000 shares from the underwriters at the same price; settlement expected on or about 12 November 2026. LifeStance announcement, reported by Investing.com · as of
- Q3 2026 revenue was $455.9M, up 25%; Center Margin was $161.4M, up 38%; adjusted EBITDA was $68.4M, up 70%, or 15.0% of revenue; net income was $22.4M against $1.1M a year earlier. LifeStance Q3 2026 press release (8-K exhibit 99.1) · as of
- Full-year 2026 guidance rose to revenue of $1.741-1.761B, Center Margin of $599-613M and adjusted EBITDA of $242-250M; adjusted-EBITDA guidance was previously $215-235M. LifeStance Q3 2026 press release (8-K exhibit 99.1) · as of
- Q4 2026 guidance is revenue of $446-466M, Center Margin of $149-163M and adjusted EBITDA of $56-64M. LifeStance Q3 2026 press release (8-K exhibit 99.1) · as of
- Clinicians rose 11% to 8,863 and visits rose 17% to 2.7 million; total revenue per visit rose 7% to $170, mainly on payer rate increases. LifeStance Q3 2026 press release; Q3 2026 earnings call · as of
- TPG reported an open-market sale of 18,409,705 LifeStance shares at $12.29 on 11 September 2026. SEC Form 4 filed 15 September 2026 · as of
- Holders sold 25 million shares at $7.04, with TPG selling about 20.7 million and Summit Partners about 4.3 million; LifeStance bought back 7 million of the shares. Reuters, via Tiger Brokers news · as of
- Barclays raised its LifeStance target to $18 from $15 and kept Overweight on 11 November 2026, after BTIG ($20, Buy), Canaccord Genuity ($16, Buy) and KeyBanc ($17, Overweight) raised targets on 5 November 2026 and 6 November 2026. Barclays note as reported 11 November 2026; Benzinga analyst-ratings headlines · as of
Sources
- LifeStance Health prices 45M share secondary offering at $13.12 · investing.com ·
- LifeStance Health Group, Inc. - Form 8-K - FY2026 · sec.gov ·
- LifeStance (LFST) Q3 2026 Earnings Call Transcript · fool.com ·
- LifeStance Health Group (NASDAQ:LFST) Price Target Raised to $20.00 · marketbeat.com ·
- LifeStance Health prices secondary offering of 22.25M shares at $12.35 · streetinsider.com
- BUZZ-LifeStance Health slides as TPG slices stake in $176 mln secondary offering · itiger.com ·
Related · shared themes
AGL
agilon health
agilon health roughly doubled its 2026 adjusted EBITDA guidance to $145–$155 million after a second profitable quarter, giving the shares a…
BTSG
BrightSpring Health Services
BrightSpring Health Services is growing profit faster than revenue, with third-quarter 2026 adjusted EBITDA up 42% on specialty pharmacy…
TDOC
Teladoc Health
Teladoc Health's Q3 2026 beat and fast-growing BetterHelp insurance revenue give the shares a modest edge over the S&P 500. The refinancing…
UNH
UnitedHealth Group
UnitedHealth Group's earnings recovery, with 2026 adjusted EPS guided to at least $20.50 and a buyback widened by 50 million shares, gives…